NPM1 FLT3 Mutation Analysis
Comprehensive Genetic Testing for Acute Myeloid Leukemia
The NPM1 FLT3 Mutation Analysis represents a cutting-edge molecular diagnostic approach specifically designed for patients with acute myeloid leukemia (AML). This sophisticated genetic test plays a pivotal role in modern hematology oncology by detecting critical mutations that significantly influence treatment strategies and patient outcomes. As AML treatment becomes increasingly personalized, understanding the genetic landscape of each patient’s leukemia has become essential for optimal care.
What This Test Measures and Detects
This advanced genetic analysis specifically targets two crucial gene mutations:
- NPM1 Mutations: Detects mutations in the Nucleophosmin 1 gene, which occur in approximately 30% of adult AML cases and are generally associated with favorable prognosis when occurring without FLT3-ITD mutations
- FLT3 Mutations: Identifies both internal tandem duplications (FLT3-ITD) and tyrosine kinase domain (FLT3-TKD) mutations in the FMS-like tyrosine kinase 3 gene
- Mutation Burden Assessment: Provides quantitative analysis of mutation load, particularly important for FLT3-ITD mutations where allelic ratio impacts treatment decisions
Who Should Consider This Test
This genetic analysis is particularly recommended for:
- Newly diagnosed acute myeloid leukemia patients for comprehensive risk stratification
- Patients experiencing unexplained fatigue, bruising, or recurrent infections
- Individuals with abnormal blood counts requiring further investigation
- Patients being evaluated for targeted therapy options in AML treatment
- Those requiring prognostic assessment to guide treatment intensity decisions
- Patients with family history of hematological malignancies
Key Benefits of NPM1 FLT3 Testing
Undergoing this comprehensive genetic analysis provides numerous clinical advantages:
- Personalized Treatment Planning: Results directly influence chemotherapy intensity decisions and eligibility for targeted therapies
- Accurate Prognostic Assessment: NPM1/FLT3 mutation status is a critical component of modern AML risk stratification systems
- Targeted Therapy Guidance: FLT3 mutations may indicate responsiveness to specific FLT3 inhibitors like midostaurin and gilteritinib
- Treatment Monitoring: Provides baseline genetic profile for minimal residual disease monitoring during treatment
- Clinical Trial Eligibility: Mutation status often determines eligibility for novel therapeutic clinical trials
Understanding Your Test Results
Your NPM1 FLT3 mutation analysis results will fall into several categories:
- Favorable Risk Profile: NPM1 mutation without FLT3-ITD typically indicates better prognosis and may allow for less intensive consolidation therapy
- Intermediate Risk: Isolated FLT3-TKD mutations or wild-type status for both genes generally falls into intermediate risk category
- Adverse Risk: FLT3-ITD mutations, particularly with high allelic ratio, indicate higher relapse risk and may warrant more aggressive treatment approaches
- Therapeutic Implications: FLT3 mutations may qualify patients for FLT3 inhibitor therapy in combination with standard chemotherapy
It’s crucial to discuss your specific results with your hematologist or oncologist, as interpretation depends on the complete clinical picture including other cytogenetic and molecular findings.
Test Pricing Information
| Test Name | Discount Price | Regular Price |
|---|---|---|
| NPM1 FLT3 Mutation Analysis | $300 USD | $400 USD |
Nationwide Testing Availability
We have diagnostic branches conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing standards regardless of location.
Take Control of Your Health Journey
Don’t leave your treatment decisions to chance. The NPM1 FLT3 Mutation Analysis provides critical genetic information that can significantly impact your AML treatment pathway and overall prognosis. Our experienced genetic counselors and hematology specialists are available to help you understand your results and their implications for your care.
Ready to schedule your NPM1 FLT3 Mutation Analysis? Contact our dedicated patient care team today at +1(267) 388-9828 or book your appointment online. Take the first step toward personalized leukemia care with comprehensive genetic testing from America’s leading diagnostic provider.
